Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Noopur Raje, M.D.

Co-Author

This page shows the publications co-authored by Noopur Raje and Diana Cirstea.
Connection Strength

4.182
  1. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. . 2014 Nov; 13(11):2489-500.
    View in: PubMed
    Score: 0.604
  2. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec; 27(12):2366-75.
    View in: PubMed
    Score: 0.557
  3. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010 Apr; 9(4):963-75.
    View in: PubMed
    Score: 0.445
  4. Future novel single agent and combination therapies. Cancer J. 2009 Nov-Dec; 15(6):511-8.
    View in: PubMed
    Score: 0.432
  5. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res. 2016 06; 31(6):1225-34.
    View in: PubMed
    Score: 0.167
  6. Role of decorin in multiple myeloma (MM) bone marrow microenvironment. J Bone Miner Res. 2015 Mar; 30(3):465-70.
    View in: PubMed
    Score: 0.156
  7. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015 May; 169(3):423-34.
    View in: PubMed
    Score: 0.156
  8. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.147
  9. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014 Sep; 28(9):1892-901.
    View in: PubMed
    Score: 0.145
  10. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia. 2013 Aug; 27(8):1715-21.
    View in: PubMed
    Score: 0.136
  11. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96.
    View in: PubMed
    Score: 0.135
  12. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012 Mar 15; 119(11):2579-89.
    View in: PubMed
    Score: 0.126
  13. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71.
    View in: PubMed
    Score: 0.119
  14. A novel role for CCL3 (MIP-1a) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011 Jul; 25(7):1174-81.
    View in: PubMed
    Score: 0.119
  15. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9.
    View in: PubMed
    Score: 0.111
  16. Novel therapeutic targets for multiple myeloma. Future Oncol. 2010 Mar; 6(3):407-18.
    View in: PubMed
    Score: 0.111
  17. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36.
    View in: PubMed
    Score: 0.110
  18. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39.
    View in: PubMed
    Score: 0.107
  19. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May; 23(5):961-70.
    View in: PubMed
    Score: 0.102
  20. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep. 2015 Feb 10; 10(5):755-770.
    View in: PubMed
    Score: 0.039
  21. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
    View in: PubMed
    Score: 0.028
  22. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
    View in: PubMed
    Score: 0.028
  23. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
    View in: PubMed
    Score: 0.026
  24. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009 Sep; 23(9):1679-86.
    View in: PubMed
    Score: 0.026
  25. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71.
    View in: PubMed
    Score: 0.024
  26. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007 Nov 15; 110(10):3744-52.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.